{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:52Z","timestamp":1707524632223},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,22]]},"DOI":"10.7759\/cureus.28270","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T18:36:42Z","timestamp":1661193402000},"source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab Failure in Treating Dermatomyositis-Associated Pruritus"],"prefix":"10.7759","author":[{"given":"Margaret A","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Shevchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Quartey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane ME","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020, 82:267-81. 10.1016\/j.jaad.2019.06.1309","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.25251\/skin.5.3.19","article-title":"Treatment of refractory pruritus with dupilumab in a Patient with dermatomyositis","volume":"5","author":"Bowers N","year":"2021","unstructured":"Bowers N, Huang W. Treatment of refractory pruritus with dupilumab in a Patient with dermatomyositis. SKIN. 2021, 5:319-21. 10.25251\/skin.5.3.19","journal-title":"SKIN"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi NA","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016, 15:35-50. 10.1038\/nrd4624","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg JI","year":"2020","unstructured":"Silverberg JI, Yosipovitch G, Simpson EL, et al.. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020, 82:1328-36. 10.1016\/j.jaad.2020.02.060","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"9","author":"Kim HJ","unstructured":"Kim HJ, Zeidi M, Bonciani D, et al.. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. 9:669-78. 10.1111\/bjd.16498","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon SR","year":"2004","unstructured":"Dillon SR, Sprecher C, Hammond A, et al.. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004, 5:752-60. 10.1038\/ni1084","journal-title":"Nat Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky E","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al.. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019, 143:155-72. 10.1016\/j.jaci.2018.08.022","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine MD","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001, 345:747-55. 10.1056\/NEJMra993360","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70544-x","article-title":"Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis","volume":"40","author":"Jolles S","year":"1999","unstructured":"Jolles S, Hughes J, Rustin M. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. J Am Acad Dermatol. 1999, 40:121-3. 10.1016\/s0190-9622(99)70544-x","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima K","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020, 383:141-50. 10.1056\/NEJMoa1917006","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/106265-dupilumab-failure-in-treating-dermatomyositis-associated-pruritus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:28Z","timestamp":1707507508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/106265-dupilumab-failure-in-treating-dermatomyositis-associated-pruritus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.28270","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}